Company Description
Haemonetics Corporation, a healthcare company, provides medical products and solutions.
It operates through three segments: Plasma, Blood Center, and Hospital.
The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system.
In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries.
It markets and sells its products through direct sales force, independent distributors, and sales representatives.
Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Country | United States |
IPO Date | May 10, 1991 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 3,657 |
CEO | Christopher A. Simon |
Contact Details
Address: 125 Summer Street Boston, Massachusetts United States | |
Website | https://www.haemonetics.com |
Stock Details
Ticker Symbol | HAE |
Exchange | NYSE |
Fiscal Year | May - April |
Reporting Currency | USD |
CIK Code | 0000313143 |
CUSIP Number | 405024100 |
ISIN Number | US4050241003 |
Employer ID | 04-2882273 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Christopher A. Simon | Chief Executive Officer, President & Director |
James C. D'Arecca CPA | Chief Financial Officer, Executive Vice President & Financial Officer |
Dr. Jan Hartmann M.D. | Senior Vice President & Chief Medical Officer |
Farris Maryanne Maunsell | Vice President, Chief Accounting Officer & Principal Accounting Officer |
Josep Lluis Llorens | Executive Vice President of Global Manufacturing & Supply Chain |
Laurie A. Miller | Senior Vice President & Chief Human Resources Officer |
Michelle L. Basil J.D. | Executive Vice President, General Counsel & Secretary |
Olga Guyette | Senior Director of Investor Relations |
Rajeev Varma | Senior Vice President of Strategy & Corporate Development |
Stewart W. Strong | President of Global Hospital |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 03, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 07, 2024 | 10-Q | Quarterly Report |
Nov 07, 2024 | 8-K | Current Report |
Nov 05, 2024 | 4 | Filing |
Sep 18, 2024 | 4 | Filing |
Sep 16, 2024 | 8-K | Current Report |
Sep 03, 2024 | 4 | Filing |